Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (3) : antiviral therapy

AK0406: New Long-Acting Influenza Antiviral Approved in China

AK0406: New Long-Acting Influenza Antiviral Approved in China
08/18/2026 | Companies
Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza...
AFC, AK0406, antigenic drift, antiviral drug, antiviral drug-Fc conjugate, antiviral therapy, ArkBio, Australia, biopharmaceuticals, China, clinical development, drug development, global clinical development, HREC, IND approval, infectious diseases, influenza, influenza A, influenza B, influenza prevention, influenza prophylaxis, influenza vaccines, long-acting antiviral, NMPA, Phase I clinical trial, preclinical studies, prophylactic treatment, seasonal influenza, Shanghai Ark Biopharmaceutical, therapeutic treatment

Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate

Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate
07/27/2026 | Companies
Decoy Therapeutics Inc, a biotechnology company focused on developing Designable Multi-Antivirals (D-MAVs), has announced that one of its D-MAV candidates has demonstrated in vitro effectiveness against the wild-type Ebola Zaire virus during testing conducted at the Texas Biomedical Research...
antiviral platform, antiviral therapy, arenaviruses, biotechnology, biotechnology news, broad-spectrum antivirals, coronavirus, D-MAV, DCOY, Decoy Therapeutics, Democratic Republic of the Congo, Designable Multi-Antivirals, drug development, Ebola, Ebola Zaire virus, emerging viruses, FDA Tropical Disease Priority Review Voucher, filoviruses, IMP3ACT platform, in vitro study, infectious disease treatment, infectious diseases, Lassa fever virus, Marburg virus, pandemic preparedness, pharmaceutical research, Texas Biomedical Research Institute, Uganda, viral fusion machinery, viral research

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey
04/03/2025 | Companies
In 2006, Tomas Cihlar was well aware that, despite initial successes with combination therapy, HIV continued to be a global challenge with limited treatment options. At the time, he had been researching virology at Gilead for 12 years, and the first once-daily, single-tablet regimen for HIV...
antiviral therapy, biopharmaceuticals, biotechnology, breakthrough medicine, clinical trials, drug discovery, drug resistance, Gilead, global health, healthcare innovation, HIV, HIV prevention, HIV research, HIV treatment, medical innovation, medical science, pharmaceutical development, Tomas Cihlar, viral capsid, virology


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com